Keytruda three negative breast cancer latest data positive Tecentriq failed

Currently, Roche's tecentriq is the only tumor immunotherapy approved for the treatment of triple negative breast cancer (TNBC) However, the latest clinical data of keysruda in refractory TNBC seems to be expected to change this situation On December 12, at the 42nd San Antonio Breast Cancer Symposium (sabcs2019) in 2019, mosadon published the latest subgroup analysis data from the phase 3 clinical study (keynote-522) The results showed that 64.8% of TNBC patients in keytruda + chemotherapy group could achieve the complete pathological response, that is, there were no cancer cells in the tissues removed by surgery, while the proportion in the chemotherapy group was 44.1% This data once again supports the data published in September on keytruda's treatment of TNBC At that time, the data showed that 64.8% of patients in keytruda's chemotherapy combination achieved complete pathological remission, and 51.2% in the chemical group alone In addition, the keynote-522 study also showed that patients treated with keytruda chemotherapy had a 37% lower risk of postoperative recurrence compared to patients treated with chemotherapy alone, although this result was not statistically significant Roy Baynes, chief medical officer and head of global clinical development at MSD, said the results looked impressive in the relatively early stages of the trial Although keytruda does not show significant benefit in preventing recurrence, achieving complete pathological remission is usually a "good predictor" of non recurrence Unlike keytruda, the latest development of Roche tecentriq is not optimistic On the same day, Roche also released new data (neotripapdl1 study) After chemotherapy, tecentriq treatment can not completely relieve TNBC patients After chemotherapy but before operation, 43.5% of the patients who received tecentriq treatment did not find any sign of cancer cells after operation, and 40.8% of the patients in the chemotherapy group had no statistically significant difference When Roche tries to promote the listing process of keytruda, such a result will undoubtedly bring disadvantage to Roche In October, tecentriq Abraxane was rejected by ingnice, although the treatment is considered a cost-effective TNBC treatment option The UK regulator acknowledged that the combination delayed disease progression by 2.5 months in patients with tumor expressing biomarker PD-L1, beating the placebo chemotherapy combination, but believed that the clinical data obtained were still insufficient compared with other chemicals (including paclitaxel and docetaxel) Nice's refusal forced Roche to add new data or consider offering greater discounts.